solagran announcement out, page-66

Jezza,

Regarding the liver, biopsy would have been the way to go. With hep, I guess their would be virus assays and with cancer, various forms of imaging would provide an answer.

As for what would the price be if it did all of those things, a reasonable price would be well, well, well in excess of $200 million. The best bit is, though, to get a share price like that all SLA has to do if provide the definitive data they claim they have. If you were SLA, why wouldn't you do that? We know what is in BioA. We know what is in ropren. Given we already know what they stuff is, patents can't be an issue. Jezza, the argument just doesn't hold up.

Cheers,

Bill